The Company

Voxeleron is the innovative leader in AI-backed ophthalmic image analysis, delivering a powerful platform that interprets millions of measurements across multiple formats to translate clinical research data into valid, actionable results. By optimizing all aspects of clinical eye research, from initial trial recruitment through post-hoc analysis, Voxeleron is bringing comprehensive eye health into focus and helping eradicate diseases affecting tens of millions.

Founders

Jonathan Oakley

Jonathan Oakley has a B.Sc. in Computer Science from the University of York, England, a Masters from University College, London, and a Ph.D. in medical image processing from the Swiss Federal Institute of Technology (ETHZ). Since then, he has spent almost two decades working on image processing and machine learning algorithm development for KLA-Tencor, Fujifilm and Carl Zeiss Meditec Inc. His research interests are primarily in medical image processing, with a clear emphasis on ophthalmic applications as evidenced by his publication list.

Daniel Russakoff

Daniel Russakoff received an A.B. in Geophysics from Harvard University and his Ph.D. in Computer Science from Stanford. His research interests are in computer vision and pattern recognition in general, and biomedical image analysis in particular. He has authored numerous conference and journal papers and holds several patents on topics ranging from stereo vision to medical image registration. He has worked as a Computer Scientist at the National Institute of Standards and Technology and as Chief Scientist at Fujifilm’s San Jose Research Lab. His more recent work has been using probabilistic shape analysis and machine learning for segmentation of deformable structures in 2D and 3D radiological images.

Management

Manabu Tokunaga

Manabu Tokunaga is Voxeleron’s director of software and the chief architect of the iNebula product.  He has more than 35 years of PACS engineering experience, is recognized throughout the industry as an expert, and was the founder of Stentor, who were acquired by Philips Medical Systems Global PACS Business Unit.

Scientific Advisory Board

We are currently in the process of recruiting a scientific advisory board, so please stay tuned for updates.  A large focus of our research and development has been in neurological applications of ophthalmic imaging, which we will continue to do.  Our concentration, however, has shifted toward ocular diseases, with a focus on prognostics using deep learning.  In light of this, we are assembling a Scientific Advisory Board to offer expertise and help guide this research to address the relevant and pressing problems.  Further updates to follow.